UTHR United Therapeutics Corporation Stock Quote

UTHR [NASD]

Index	-	P/E	19.46	EPS (ttm)	10.28	Insider Own	0.20%	Shs Outstand	44.80M	Perf Week	-4.84%
Market Cap	9.01B	Forward P/E	12.40	EPS next Y	16.13	Insider Trans	-23.08%	Shs Float	43.44M	Perf Month	-1.62%
Income	470.90M	PEG	12.97	EPS next Q	3.56	Inst Own	99.10%	Short Float	7.45%	Perf Quarter	12.10%
Sales	1.59B	P/S	5.66	EPS this Y	583.80%	Inst Trans	-0.12%	Short Ratio	9.90	Perf Half Y	17.62%
Book/sh	81.24	P/B	2.46	EPS next Y	42.21%	ROA	10.20%	Target Price	221.70	Perf Year	87.57%
Cash/sh	43.69	P/C	4.58	EPS next 5Y	1.50%	ROE	13.70%	52W Range	98.37 - 216.90	Perf YTD	31.81%
Dividend	-	P/FCF	16.09	EPS past 5Y	-1.90%	ROI	10.90%	52W High	-7.75%	Beta	0.49
Dividend %	-	Quick Ratio	7.20	Sales past 5Y	0.20%	Gross Margin	92.50%	52W Low	103.40%	ATR	4.76
Employees	950	Current Ratio	7.40	Sales Q/Q	23.30%	Oper. Margin	27.50%	RSI (14)	41.41	Volatility	2.48% 2.18%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	51.30%	Profit Margin	29.60%	Rel Volume	1.78	Prev Close	205.14
Shortable	Yes	LT Debt/Eq	0.22	Earnings	Aug 04 BMO	Payout	0.00%	Avg Volume	327.00K	Price	200.08
Recom	1.90	SMA20	-4.02%	SMA50	0.88%	SMA200	11.29%	Volume	583,220	Change	-2.47%

Jul-14-21

Upgrade

Argus

Hold → Buy

$205

Apr-26-21

Resumed

Credit Suisse

Outperform

$196

Feb-01-21

Upgrade

H.C. Wainwright

Neutral → Buy

$125 → $195

Sep-14-20

Resumed

JP Morgan

Overweight

$142

Jun-25-20

Reiterated

H.C. Wainwright

Neutral

$85 → $125

Mar-10-20

Upgrade

Jefferies

Hold → Buy

$123

Feb-27-20

Upgrade

Cowen

Market Perform → Outperform

$119 → $145

Jan-31-20

Upgrade

JP Morgan

Neutral → Overweight

$120

Dec-03-19

Initiated

BofA/Merrill

Underperform

Aug-01-19

Upgrade

Ladenburg Thalmann

Neutral → Buy

$103 → $106

Aug-01-19

Upgrade

Jefferies

Underperform → Hold

$90

Jul-01-19

Upgrade

Credit Suisse

Neutral → Outperform

$98 → $101

May-17-19

Upgrade

UBS

Sell → Neutral

$115 → $94

May-09-19

Upgrade

Credit Suisse

Underperform → Neutral

$98

Oct-12-18

Upgrade

Standpoint Research

Hold → Buy

Aug-08-18

Downgrade

Credit Suisse

Neutral → Underperform

Apr-03-18

Upgrade

Credit Suisse

Underperform → Neutral

Feb-22-18

Reiterated

Barclays

Underweight

$115 → $105

Jan-18-18

Resumed

Credit Suisse

Underperform

$118

Dec-27-17

Reiterated

Wedbush

Outperform

$213 → $232

Sep-10-21 06:00AM	United Therapeutics Releases its Annual Corporate Responsibility Report PR Newswire
Sep-07-21 09:54AM	United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients Benzinga
06:00AM	United Therapeutics Presents Tyvaso DPI BREEZE Clinical Data At The European Respiratory Society International Congress 2021 PR Newswire
Sep-03-21 11:31AM	United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue? Zacks
Aug-25-21 06:00AM	United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month PR Newswire
Aug-24-21 06:00AM	United Therapeutics to Present Tyvaso DPI BREEZE Clinical Data at the European Respiratory Society International Congress 2021 PR Newswire
Aug-12-21 11:30AM	MannKind Corporation (MNKD) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 10:09AM	United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up Zacks
Aug-04-21 05:56PM	Why United Therapeutics Blasted 14% Higher Today Motley Fool +14.08%
12:30PM	United Therapeutics Corporation (UTHR) Q2 2021 Earnings Call Transcript Motley Fool
07:15AM	United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates Zacks
06:00AM	United Therapeutics Corporation Reports Second Quarter 2021 Financial Results PR Newswire
Aug-03-21 06:00AM	United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Jul-29-21 08:16AM	Is United Therapeutics (NASDAQ:UTHR) A Risky Investment? Simply Wall St.
Jul-28-21 03:03PM	United Therapeutics (UTHR) to Report Q2 Results: Wall Street Expects Earnings Growth Zacks
06:00AM	United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021 PR Newswire
Jul-21-21 10:06AM	Do Hedge Funds Love JOYY Inc. (YY)? Insider Monkey
Jun-30-21 06:00AM	United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study PR Newswire
Jun-23-21 01:12PM	Hedge Funds Have Never Been This Bullish On United Therapeutics Corporation (UTHR) Insider Monkey
Jun-17-21 09:40AM	United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag Zacks
Jun-16-21 10:59AM	MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI With New Drug Application Acceptance From The FDA PR Newswire
07:26AM	MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension Benzinga
06:15AM	MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI With New Drug Application Acceptance From the FDA GlobeNewswire
06:00AM	United Therapeutics Announces FDA Acceptance of Tyvaso DPI New Drug Application For Priority Review PR Newswire
05:04AM	MannKind Shares Rise as Partner's Drug Gets FDA Priority Review TheStreet.com
Jun-14-21 10:01AM	Declining Stock and Decent Financials: Is The Market Wrong About United Therapeutics Corporation (NASDAQ:UTHR)? Simply Wall St.
Jun-07-21 06:00AM	United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia PR Newswire
Jun-04-21 11:31AM	Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report? Zacks
08:06AM	United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF Zacks
Jun-03-21 06:00AM	United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis PR Newswire
May-25-21 06:00AM	United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference PR Newswire
May-06-21 09:32AM	United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat Zacks
May-05-21 03:01PM	United Therapeutics Corp (UTHR) Q1 2021 Earnings Call Transcript Motley Fool
07:30AM	United Therapeutics (UTHR) Lags Q1 Earnings Estimates Zacks
07:15AM	United Therapeutics Corp. to Host Earnings Call ACCESSWIRE
06:00AM	United Therapeutics Corporation Reports First Quarter 2021 Financial Results PR Newswire
Apr-28-21 12:34PM	Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline Zacks
07:40AM	If You Had Bought United Therapeutics (NASDAQ:UTHR) Shares A Year Ago You'd Have Earned 86% Returns Simply Wall St.
Apr-26-21 10:20AM	United Therapeutics Gets a Second Wind TheStreet.com
06:00AM	United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021 PR Newswire
Apr-19-21 06:00AM	United Therapeutics Announces Submission of Tyvaso DPI New Drug Application to FDA PR Newswire
06:00AM	Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI With New Drug Application Submitted to the FDA GlobeNewswire
Apr-06-21 03:16PM	Is UTHR Stock A Buy or Sell? Insider Monkey
Apr-05-21 08:13AM	United Therapeutics (UTHR) Gains on Tyvaso Label Expansion Zacks
Apr-02-21 07:07AM	United Therapeutics Receives FDA Approval For Tyvaso Therapy; Shares Pop 15% SmarterAnalyst
06:50AM	This Pharma Can Breathe New Life Into Your Portfolio Motley Fool
Apr-01-21 08:25AM	5 Top Stock Gainers Thursday: Funko, United Therapeutics, Wayfair TheStreet.com +14.99%
08:24AM	United Therapeutics Jumps as FDA Clears Hypertension Drug TheStreet.com
06:00AM	United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease PR Newswire
Mar-26-21 11:31AM	Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report? Zacks
Mar-24-21 06:00AM	United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum PR Newswire
Mar-09-21 06:00AM	United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference PR Newswire
Mar-03-21 11:05AM	Looking Into United Therapeutics's Return On Capital Employed Benzinga
07:38AM	United Therapeutics Pulls Plug On Trevyent Development Benzinga
Feb-27-21 03:05AM	United Therapeutics Corporation Just Missed Earnings - But Analysts Have Updated Their Models Simply Wall St.
Feb-25-21 02:30PM	United Therapeutics Corp (UTHR) Q4 2020 Earnings Call Transcript Motley Fool
Feb-24-21 04:30PM	United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference PR Newswire
02:30PM	United Therapeutics Corp (UTHR) Q4 2020 Earnings Call Transcript Motley Fool
07:15AM	United Therapeutics Corp. to Host Earnings Call ACCESSWIRE
07:07AM	Recap: United Therapeutics Q4 Earnings Benzinga
Feb-18-21 05:20AM	Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med Benzinga
Feb-17-21 06:00AM	United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021 PR Newswire
Feb-10-21 06:00AM	United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin® PR Newswire
Jan-28-21 04:51PM	Why Proto Labs Stock Crashed Back 12.6% Today Motley Fool +5.52%
06:00AM	United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI Meets Primary Objective PR Newswire
Jan-27-21 04:13PM	Here's Why 3D Systems Stock Has Catapulted 290% In Three Weeks Investor's Business Daily -5.50%
08:30AM	3D Systems Announces Breakthrough in Bioprinting Technology and Expansion of Regenerative Medicine Initiative GlobeNewswire
Jan-21-21 11:00PM	12 Biggest Companies with Gay CEOs Insider Monkey
Jan-20-21 10:30AM	Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA Zacks
Jan-13-21 05:01PM	United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease PR Newswire
Jan-07-21 09:28AM	RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation Zacks
Jan-04-21 06:00AM	United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire
05:04AM	Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Stock Performance Influenced By Its Fundamentals In Any Way? Simply Wall St.
Dec-28-20 09:00AM	Y-mAbs Announces Sale of Priority Review Voucher GlobeNewswire
06:00AM	United Therapeutics Announces Agreement To Acquire Priority Review Voucher PR Newswire
Dec-20-20 07:03PM	Is UTHR A Good Stock To Buy Now? Insider Monkey
Dec-15-20 04:13PM	United Therapeutics Meets 80-Plus RS Rating Benchmark; Hits New High Investor's Business Daily
Dec-09-20 06:00AM	United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis PR Newswire
Nov-27-20 11:31AM	United Therapeutics (UTHR) Up 2.3% Since Last Earnings Report: Can It Continue? Zacks
Nov-26-20 09:14AM	Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter Zacks
Nov-24-20 06:00AM	United Therapeutics Releases Its First Corporate Responsibility Report PR Newswire
Nov-10-20 06:00AM	United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference PR Newswire
Nov-05-20 01:20PM	These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely Simply Wall St.
Nov-02-20 05:55AM	United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference PR Newswire
Oct-28-20 02:31PM	United Therapeutics Corp (UTHR) Q3 2020 Earnings Call Transcript Motley Fool +6.99%
12:13PM	United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates Zacks
07:30AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates Zacks
07:22AM	Recap: United Therapeutics Q3 Earnings Benzinga
07:00AM	United Therapeutics Corp. to Host Earnings Call ACCESSWIRE
06:00AM	United Therapeutics Corporation Reports Third Quarter 2020 Financial Results PR Newswire
Oct-27-20 11:59AM	Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More Zacks
09:12AM	Was The Smart Money Right About United Therapeutics Corporation (UTHR)? Insider Monkey
Oct-22-20 06:00AM	United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting PR Newswire
Oct-21-20 06:00AM	United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020 PR Newswire
Oct-15-20 06:00AM	United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020 PR Newswire
Sep-21-20 07:00AM	CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant PR Newswire
Sep-17-20 01:01PM	How Much Did United Therapeutics'(NASDAQ:UTHR) Shareholders Earn From Share Price Movements Over The Last Five Years? Simply Wall St.
Sep-16-20 06:00AM	United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit PR Newswire
Sep-11-20 06:00AM	United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors PR Newswire
Sep-09-20 10:43AM	Hedge Funds Are Absolutely Crazy About United Therapeutics Corporation (UTHR) Insider Monkey

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BENKOWITZ MICHAEL	President and COO	Sep 16	Option Exercise	53.83	4,000	215,320	6,235	Sep 17 04:39 PM
MAHON PAUL A	EVP & General Counsel	Sep 16	Option Exercise	111.00	6,000	666,000	42,369	Sep 16 04:31 PM
MAHON PAUL A	EVP & General Counsel	Sep 16	Sale	204.08	6,000	1,224,467	36,369	Sep 16 04:31 PM
BENKOWITZ MICHAEL	President and COO	Sep 14	Option Exercise	53.83	4,000	215,320	6,235	Sep 15 04:33 PM
BENKOWITZ MICHAEL	President and COO	Sep 09	Option Exercise	53.83	4,000	215,320	6,235	Sep 10 05:39 PM
BENKOWITZ MICHAEL	President and COO	Sep 07	Option Exercise	53.83	4,000	215,320	6,235	Sep 08 06:19 PM
MAHON PAUL A	EVP & General Counsel	Sep 02	Option Exercise	111.00	6,000	666,000	42,369	Sep 02 05:25 PM
BENKOWITZ MICHAEL	President and COO	Sep 02	Option Exercise	53.83	4,000	215,320	6,235	Sep 02 05:24 PM
MAHON PAUL A	EVP & General Counsel	Sep 02	Sale	210.94	6,000	1,265,650	36,369	Sep 02 05:25 PM
BENKOWITZ MICHAEL	President and COO	Aug 31	Option Exercise	53.83	4,000	215,320	6,235	Sep 01 04:31 PM
BENKOWITZ MICHAEL	President and COO	Aug 26	Option Exercise	53.83	4,000	215,320	6,235	Aug 27 04:32 PM
BENKOWITZ MICHAEL	President and COO	Aug 24	Option Exercise	53.83	4,000	215,320	6,235	Aug 24 06:27 PM
MAHON PAUL A	EVP & General Counsel	Aug 23	Option Exercise	111.00	6,000	666,000	42,369	Aug 24 04:33 PM
MAHON PAUL A	EVP & General Counsel	Aug 23	Sale	205.82	6,000	1,234,901	36,369	Aug 24 04:33 PM
BENKOWITZ MICHAEL	President and COO	Aug 19	Option Exercise	53.83	4,000	215,320	6,235	Aug 20 04:31 PM
BENKOWITZ MICHAEL	President and COO	Aug 17	Option Exercise	53.83	4,000	215,320	6,235	Aug 18 04:31 PM
BENKOWITZ MICHAEL	President and COO	Aug 12	Option Exercise	53.83	4,000	215,320	6,235	Aug 16 08:02 AM
BENKOWITZ MICHAEL	President and COO	Aug 10	Option Exercise	53.83	4,000	215,320	6,235	Aug 11 04:31 PM
CAUSEY CHRISTOPHER	Director	Aug 06	Option Exercise	76.36	2,610	199,300	3,360	Aug 06 04:31 PM
CAUSEY CHRISTOPHER	Director	Aug 06	Sale	210.00	2,610	548,100	750	Aug 06 04:31 PM
MAHON PAUL A	EVP & General Counsel	Aug 05	Option Exercise	94.96	5,500	522,280	41,869	Aug 06 04:32 PM
BENKOWITZ MICHAEL	President and COO	Aug 05	Option Exercise	53.83	4,000	215,320	6,235	Aug 06 04:33 PM
PATUSKY CHRISTOPHER	Director	Aug 04	Option Exercise	63.90	2,000	127,800	5,980	Aug 06 04:34 PM
MAHON PAUL A	EVP & General Counsel	Jul 15	Option Exercise	94.96	6,000	569,760	42,369	Jul 16 04:31 PM
MAHON PAUL A	EVP & General Counsel	Jul 01	Option Exercise	94.96	6,000	569,760	42,369	Jul 02 04:31 PM
Mesa Nilda	Director	Jun 26	Option Exercise	0.00	1,680	0	1,680	Jun 29 04:40 PM
Thompson Tommy G	Director	Jun 26	Option Exercise	0.00	1,680	0	6,520	Jun 29 04:39 PM
PATUSKY CHRISTOPHER	Director	Jun 26	Option Exercise	0.00	1,680	0	3,980	Jun 29 04:36 PM
DWEK RAYMOND	Director	Jun 26	Option Exercise	0.00	3,360	0	3,360	Jun 29 04:34 PM
Olian Judy D.	Director	Jun 26	Option Exercise	0.00	3,360	0	9,150	Jun 29 04:33 PM
Giltner Richard	Director	Jun 26	Option Exercise	0.00	3,360	0	11,710	Jun 29 04:31 PM
KURZWEIL RAY	Director	Jun 26	Option Exercise	0.00	1,680	0	9,220	Jun 28 06:54 PM
SULLIVAN LOUIS W	Director	Jun 26	Option Exercise	0.00	1,680	0	11,100	Jun 28 06:17 PM
Klein Katherine J	Director	Jun 26	Option Exercise	0.00	1,680	0	1,680	Jun 28 06:14 PM
MAHON PAUL A	EVP & General Counsel	Jun 17	Option Exercise	94.96	6,000	569,760	42,369	Jun 21 04:32 PM
MAHON PAUL A	EVP & General Counsel	Jun 03	Option Exercise	94.96	6,000	569,760	42,369	Jun 04 04:32 PM
MAHON PAUL A	EVP & General Counsel	May 20	Option Exercise	94.96	6,000	569,760	42,369	May 24 04:33 PM
SULLIVAN LOUIS W	Director	May 11	Option Exercise	75.97	30,000	2,278,950	24,420	May 12 04:34 PM
PATUSKY CHRISTOPHER	Director	May 10	Sale	190.52	100	19,052	1,200	May 10 04:31 PM
MAHON PAUL A	EVP & General Counsel	May 06	Option Exercise	94.96	6,000	569,760	42,369	May 10 04:32 PM
PATUSKY CHRISTOPHER	Director	May 06	Option Exercise	63.90	2,500	159,750	4,800	May 10 04:31 PM
DWEK RAYMOND	Director	May 05	Option Exercise	54.77	2,000	109,540	2,000	May 06 04:40 PM
DWEK RAYMOND	Director	Apr 28	Option Exercise	54.77	2,000	109,540	2,000	Apr 29 04:32 PM
DWEK RAYMOND	Director	Apr 21	Option Exercise	54.77	2,000	109,540	2,000	Apr 22 04:31 PM
MAHON PAUL A	EVP & General Counsel	Apr 15	Option Exercise	94.96	6,000	569,760	42,369	Apr 16 04:33 PM
DWEK RAYMOND	Director	Apr 14	Option Exercise	54.77	2,000	109,540	2,000	Apr 15 04:32 PM
DWEK RAYMOND	Director	Apr 07	Option Exercise	54.77	2,000	109,540	2,000	Apr 08 05:26 PM
Olian Judy D.	Director	Apr 01	Option Exercise	76.36	4,207	321,247	9,997	Apr 02 09:33 AM
MAHON PAUL A	EVP & General Counsel	Apr 01	Option Exercise	94.96	6,000	569,760	42,369	Apr 02 09:35 AM
Olian Judy D.	Director	Apr 01	Sale	184.96	4,207	778,127	5,790	Apr 02 09:33 AM
KURZWEIL RAY	Director	Mar 26	Option Exercise	54.77	3,750	205,388	11,290	Mar 29 04:31 PM
MAHON PAUL A	EVP & General Counsel	Mar 18	Option Exercise	94.96	6,000	569,760	42,369	Mar 19 04:32 PM
Olian Judy D.	Director	Mar 17	Option Exercise	76.36	2,103	160,585	7,893	Mar 19 04:32 PM
Olian Judy D.	Director	Mar 17	Sale	170.00	2,103	357,510	5,790	Mar 19 04:32 PM
Thompson Tommy G	Director	Mar 10	Option Exercise	54.77	12,350	676,410	17,190	Mar 11 04:35 PM
MAHON PAUL A	EVP & General Counsel	Mar 04	Option Exercise	94.96	6,000	569,760	42,369	Mar 05 05:26 PM
MAHON PAUL A	EVP & General Counsel	Feb 18	Option Exercise	94.96	6,000	569,760	42,131	Feb 19 04:33 PM
MAHON PAUL A	EVP & General Counsel	Feb 04	Option Exercise	94.96	6,000	569,760	42,131	Feb 05 04:31 PM
MAHON PAUL A	EVP & General Counsel	Jan 21	Option Exercise	94.96	6,000	569,760	42,131	Jan 22 04:31 PM
CAUSEY CHRISTOPHER	Director	Jan 15	Option Exercise	88.03	1,500	132,045	2,325	Jan 19 04:39 PM
MAHON PAUL A	EVP & General Counsel	Jan 07	Option Exercise	94.96	6,000	569,760	42,131	Jan 08 04:39 PM
CAUSEY CHRISTOPHER	Director	Jan 07	Option Exercise	88.03	1,500	132,045	2,325	Jan 08 04:38 PM
CAUSEY CHRISTOPHER	Director	Jan 06	Option Exercise	88.03	1,500	132,045	2,325	Jan 08 04:38 PM
Giltner Richard	Director	Jan 06	Option Exercise	48.11	10,000	481,100	18,350	Jan 08 04:36 PM
Giltner Richard	Director	Jan 05	Option Exercise	48.11	5,000	240,550	13,350	Jan 06 04:35 PM
CAUSEY CHRISTOPHER	Director	Jan 05	Option Exercise	88.03	1,500	132,045	2,325	Jan 06 04:31 PM
Giltner Richard	Director	Jan 04	Option Exercise	54.77	5,000	273,850	13,350	Apr 16 04:32 PM
CAUSEY CHRISTOPHER	Director	Dec 31	Option Exercise	88.03	7,500	660,225	8,325	Jan 04 04:30 PM
CAUSEY CHRISTOPHER	Director	Dec 23	Option Exercise	88.03	1,500	132,045	2,325	Dec 28 04:32 PM
MAHON PAUL A	EVP & General Counsel	Dec 17	Option Exercise	94.96	6,000	569,760	42,131	Dec 18 04:58 PM
Giltner Richard	Director	Dec 17	Option Exercise	54.77	5,000	273,850	13,350	Dec 18 04:56 PM
PATUSKY CHRISTOPHER	Director	Dec 08	Option Exercise	63.90	3,000	191,700	5,300	Dec 09 04:31 PM
MAHON PAUL A	EVP & General Counsel	Dec 03	Option Exercise	94.96	6,000	569,760	42,131	Dec 04 04:51 PM
DWEK RAYMOND	Director	Nov 10	Option Exercise	48.11	2,000	96,220	2,000	Nov 12 04:33 PM
MAHON PAUL A	EVP & General Counsel	Nov 05	Option Exercise	94.96	6,000	569,760	42,131	Nov 06 04:31 PM
Giltner Richard	Director	Nov 04	Option Exercise	54.77	5,000	273,850	13,350	Nov 05 04:33 PM
DWEK RAYMOND	Director	Nov 02	Option Exercise	54.77	5,000	273,850	5,000	Nov 03 04:44 PM
BENKOWITZ MICHAEL	President and COO	Nov 02	Option Exercise	63.42	28,200	1,788,420	23,748	Nov 03 04:43 PM
CAUSEY CHRISTOPHER	Director	Oct 28	Option Exercise	63.90	2,000	127,800	2,825	Oct 29 04:32 PM
CAUSEY CHRISTOPHER	Director	Oct 22	Option Exercise	63.90	2,500	159,750	3,325	Oct 23 04:32 PM
CAUSEY CHRISTOPHER	Director	Oct 16	Option Exercise	63.90	2,250	143,775	2,325	Oct 19 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience